Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (42)

2024

  1. De-imFAR phase II project: a study protocol for a cluster randomised implementation trial to evaluate the effectiveness of de-implementation strategies to reduce low-value statin prescribing in the primary prevention of cardiovascular disease

    BMJ Open, Vol. 14, Núm. 4

  2. GEDEFO-SEFH management of antineoplastic extravasations survey results

    Journal of Oncology Pharmacy Practice, Vol. 30, Núm. 1, pp. 67-77

  3. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta

    Biomedicine and Pharmacotherapy, Vol. 175

  4. Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain

    BMC Geriatrics, Vol. 24, Núm. 1

  5. Use of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury

    Clinical and Experimental Nephrology, Vol. 28, Núm. 1, pp. 13-22

2023

  1. Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs

    Farmacia Hospitalaria, Vol. 47, Núm. 2, pp. 69-74

  2. Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population

    Antibiotics, Vol. 12, Núm. 2

  3. Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment

    Pharmaceutics, Vol. 15, Núm. 8

  4. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2022

  1. Analysis of standard concentrations of continuous infusions in nine Spanish neonatal intensive care units

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 1, pp. 50-54

  2. Antineoplastic extravasation management: Consensus of the Spanish Oncology Pharmacy Group (GEDEFO)

    Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1170-1181

  3. Complicaciones óseas en pacientes con leucemia linfoblástica aguda y linfomas

    Boletín de la Sociedad Vasco-Navarra de pediatría = Euskal Herriko Pediatria Elkartearen aldizkaria, Núm. 123, pp. 37-40

  4. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Classification of antineoplastic drug-induced tissue damage: a Consensus of the Spanish Oncology Pharmacy Group

    Farmacia Hospitalaria, Vol. 45, Núm. 4, pp. 198-203

  2. Drug compatibility in neonatal intensive care units: gaps in knowledge and discordances

    European Journal of Pediatrics, Vol. 180, Núm. 7, pp. 2305-2313

  3. Intravenous drug use in neonatal intensive care units

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 6, pp. 341-345

  4. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units

    European Journal of Pediatrics, Vol. 180, Núm. 4, pp. 1169-1176

  5. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

2019

  1. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database

    American journal of therapeutics, Vol. 26, Núm. 5, pp. e589-e592

2018

  1. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review

    Clinical Pharmacokinetics, Vol. 57, Núm. 9, pp. 1107-1121